William Blair downgraded Elevation Oncology (ELEV) to Market Perform from Outperform after Concentra Biosciences agreed to acquire Elevation for 36c in cash per share plus one non-tradeable contingent value right.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ELEV:
- Elevation Oncology Merges with Concentra Biosciences
- Elevation enters into agreement to be acquired by Concentra for 36c per share
- Elevation Oncology: Hold Rating Amid Strategic Uncertainty and Financial Constraints
- Elevation Oncology Reports Q1 2025 Financial Results
- Elevation Oncology: Strategic Positioning and Financial Stability Drive Buy Rating